ABSTRACT
BACKGROUND AND OBJECTIVES: The clinical significance of anti-K11 in red cell transfusion therapy is unknown. We report the outcome of transfusion of K:11 erythrocytes into a patient with a known anti-K11 antibody. MATERIALS AND METHODS: The patient was monitored clinically following transfusion of 11 units of K:11 erythrocytes. A red cell survival study with K:11 erythrocytes and a monocyte monolayer assay (MMA) were performed. RESULTS: No adverse clinical outcome was detected. The red cell survival study showed normal survival of K:11 erythrocytes, and the MMA showed no increase in reactive monocytes. CONCLUSION: These findings suggest that K:11 red cells can safely be transfused to individuals with anti-K11 antibody.
Subject(s)
Blood Group Incompatibility/immunology , Erythrocyte Transfusion , Isoantibodies/immunology , Kell Blood-Group System/immunology , Adult , Anemia/etiology , Anemia/therapy , Duodenal Ulcer/complications , Duodenal Ulcer/surgery , Erythrocyte Aging , Female , Gastrointestinal Hemorrhage/etiology , Gastrointestinal Hemorrhage/therapy , Humans , Kidney Failure, Chronic/blood , Kidney Failure, Chronic/immunology , Kidney Failure, Chronic/therapy , Peptic Ulcer Perforation/complications , Peptic Ulcer Perforation/surgery , Postoperative Complications/therapy , Renal DialysisABSTRACT
We report a case of Castleman's disease demonstrating 18F-fluorodeoxyglucose (FDG) localization by whole-body PET imaging in a pelvic soft-tissue mass shown on abdominopelvic CT. In this case, there is mild FDG localization within pelvic Castleman's disease with standard uptake values lower than in many cases of low-grade and intermediate-grade lymphomas previously reported. FDG-PET may be of value as an imaging modality for differentiating Castleman's disease from lymphoma.
Subject(s)
Castleman Disease/diagnostic imaging , Deoxyglucose/analogs & derivatives , Fluorine Radioisotopes , Radiopharmaceuticals , Tomography, Emission-Computed , Adult , Diagnosis, Differential , Female , Fluorodeoxyglucose F18 , Humans , Lymphoma/diagnostic imaging , Pelvic Neoplasms/diagnostic imagingABSTRACT
We attempted to evaluate the role of radionuclide angiography in the routine treatment of patients receiving doxorubicin-based therapy in a university hospital setting. We identified 222 cancer patients treated with doxorubicin or who underwent radionuclide angiography with the intent to receive doxorubicin at the University of Iowa in 1989. We examined the cumulative doses of doxorubicin, results of radionuclide angiograms, cardiac risk factors, and clinical outcomes and survival of patients. Of 222 patients, 168 (76%) underwent at least one radionuclide angiogram and received doxorubicin. Only a baseline study was performed in 136 (81%) of these 168 patients. Only 32 underwent follow-up study during therapy; six patients discontinued therapy for an 11-21% decrease in left ventricular function. The mean dose of doxorubicin received was 211 mg/m2, and 193 patients (96%) received a cumulative dose <450 mg/m2. Only two patients (1%) had heart failure. A questionnaire sent to medical oncologists in Iowa showed that use of radionuclide angiography in our institution reflected practice throughout the state. The majority of patients in our population who underwent radionuclide angiography had a single baseline study, which provides little clinically useful information. The majority of patients receiving doxorubicin as currently employed can be safely treated without radionuclide angiography.
